PIB TrackerFree HPV vaccination launched for teen girls
India rolls out a nationwide single-dose HPV vaccination campaign for 14-year-old girls to push back the country's second-commonest cancer in women — cervical cancer.
What happened
- The Ministry of Health and Family Welfare told Parliament that a nationwide HPV vaccination campaign for girls aged 14 was launched on 28 February 2026.
- The vaccine offered is a single dose of Gardasil-4 (a quadrivalent Human Papillomavirus vaccine), provided free of cost at government health facilities.
- Delivery sites span the public-health pyramid: Ayushman Arogya Mandir–Primary Health Centres (AAM-PHCs), Community Health Centres (CHCs), Sub-District and District Hospitals (SDH/DHs), and Government Medical Colleges (GMCs).
- Participation is voluntary and requires mandatory parental consent; each beneficiary is registered on the U-WIN digital platform.
- The roll-out was preceded by technical guidance from SAGE, the WHO, the ICMR and the NTAGI, and by training of health staff across all 36 States and Union Territories.
- Every vaccination site is linked to a 24×7 AEFI (Adverse Events Following Immunization) management centre as a safety net.
- The campaign acts on the recommendations of the 72nd and 81st Reports of the Parliamentary Standing Committee on Health, disclosed in a Lok Sabha reply.
Background & context
Cervical cancer is among the most preventable of all cancers, yet it remains a heavy burden for Indian women — the disease is consistently reported as the second most common cancer among women in India after breast cancer, and almost all cases are caused by persistent infection with high-risk types of the Human Papillomavirus (HPV). Because HPV is sexually transmitted and the cancer it triggers takes years to develop, vaccinating girls before exposure offers a long lead-time prevention strategy. The World Health Organization's 2020 global call to eliminate cervical cancer as a public-health problem set the well-known "90–70–90" targets, of which the first is that 90% of girls be fully vaccinated against HPV by age 15. India's new campaign is the operational answer to that target.
The roll-out does not arrive in isolation. It sits inside India's Universal Immunization Programme (UIP) — one of the world's largest public-health programmes, which annually targets crores of pregnant women and infants and delivers vaccines against a basket of preventable diseases. The same digital backbone now used for HPV, the U-WIN platform, was built to digitise the UIP's records — registering every beneficiary, scheduling doses and generating verifiable vaccination certificates, modelled on the Co-WIN system used during the COVID-19 vaccination drive. Folding the HPV campaign into U-WIN means each 14-year-old girl's dose is tracked the same way an infant's routine immunisation is.
The release itself is a Lok Sabha reply that bundles the HPV campaign with a wider set of clinical-research and ethics reforms flowing from two Parliamentary Standing Committee on Health reports (the 72nd and the 81st). Those reforms include the New Drugs and Clinical Trials Rules (NDCTR), 2019, the NAITIK and SUGAM portals run by the Department of Health Research / Central Drugs Standard Control Organisation (CDSCO) for ethics-committee and regulatory registration, prospective trial registration through the Clinical Trials Registry – India (CTRI), and the ICMR National Ethical Guidelines (2017). The thread tying them together is a more rigorous, consent-driven, ethically supervised pathway from research to public roll-out — the same discipline now visible in the HPV campaign's insistence on voluntariness, written parental consent and AEFI surveillance.
For Prelims
- What it is: a publicly-funded, campaign-mode HPV vaccination drive for adolescent girls — not a standalone new "scheme" with an outlay, but an addition to the routine immunisation calendar under the Universal Immunization Programme.
- Target group: girls aged 14 (a single age cohort), the WHO-favoured window before likely HPV exposure.
- Vaccine: Gardasil-4, a quadrivalent HPV vaccine; given as a single dose, free, at government facilities. (WHO's SAGE has endorsed a single-dose schedule as effective for the primary target age, which is why one dose — not the older two- or three-dose regimen — is used.)
- Consent & nature: voluntary with mandatory parental consent — it is not compulsory.
- Digital platform: registration on U-WIN, the immunisation registry built on the Co-WIN model.
- Safety net: every site tied to a 24×7 AEFI (Adverse Events Following Immunization) management centre.
- Technical advisers: NTAGI (National Technical Advisory Group on Immunization — India's apex advisory body on vaccines), the ICMR, the WHO, and the WHO's SAGE (Strategic Advisory Group of Experts on Immunization).
- Delivery network: AAM-PHCs, CHCs, SDH/DHs and Government Medical Colleges across all 36 States/UTs.
- Parliamentary trigger: the 72nd and 81st Reports of the Parliamentary Standing Committee on Health.
- What it is NOT: it is not mandatory; it is not a multi-dose course for this cohort (a single dose is used); it is not aimed at boys in this campaign; it does not treat existing cancer — HPV vaccination is preventive, not therapeutic; and Gardasil-4 is not the nonavalent (9-valent) product — it is the quadrivalent (4-type) vaccine.
The acronym set to keep straight (a classic "match the pairs" trap): NTAGI = India's national vaccine advisory group; SAGE = the WHO's global immunisation advisory group; ICMR = the Indian Council of Medical Research, the apex biomedical research body; U-WIN = the immunisation registry platform; AEFI = the adverse-event surveillance system; UIP = the umbrella Universal Immunization Programme this campaign rides on; NDCTR 2019, NAITIK/SUGAM and CTRI = the clinical-research and ethics-registration machinery named in the same reply.
Where it fits in India's cancer-control effort: the same day's health replies sketch the surrounding architecture — the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) runs District NCD Clinics, CHC-level NCD clinics and a growing network of District Day Care Cancer Centres, with population-based screening of persons above 30 for common cancers including cervical cancer, and preventive cancer care delivered through Ayushman Arogya Mandirs. HPV vaccination is the primary-prevention arm of this effort (stopping the infection that causes the cancer), while screening and the day-care cancer centres are the secondary and tertiary arms (early detection and treatment). A complete revision note pairs the vaccine with the screen.
Why it matters
Cervical cancer kills a large number of Indian women every year, and a striking share of those deaths are avoidable because the cause — high-risk HPV — is vaccine-preventable and the disease is slow to develop and easy to screen for. The problem the campaign addresses is not medical novelty but access and reach: imported HPV vaccines have historically been expensive and used mostly by families who could pay, leaving the population most at risk under-protected. By making a single free dose available through the existing public-health pyramid and tracking it on U-WIN, the government converts a privately-purchased intervention into a routine, population-scale public good. The single-dose schedule matters operationally — it halves or thirds the logistics, follow-up and drop-out problem that multi-dose adolescent vaccination notoriously suffers, which is precisely why WHO's SAGE endorsement of one dose was the enabling step. Choosing a single 14-year age cohort, rather than a wide multi-year catch-up, keeps the campaign deliverable through schools and health centres in its first phase.
The design choices also signal a maturing immunisation governance: voluntariness with documented parental consent answers the ethical and rumour-management failures that have dogged earlier HPV efforts in India; the 24×7 AEFI linkage builds in the safety surveillance that sustains public trust; and the layering of NTAGI, ICMR, WHO and SAGE advice shows an evidence-led pathway from global guidance to national roll-out. For an aspirant, the campaign is a clean example of how a welfare-and-health-policy intervention is built — a target group defined by epidemiology, a vaccine validated by advisory bodies, a free delivery channel using existing infrastructure, a digital registry for accountability, and a consent-and-safety framework for legitimacy.